

Stanley Lipkowitz

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5316709/publications.pdf>

Version: 2024-02-01

51
papers

4,813
citations

147801

31
h-index

189892

50
g-index

53
all docs

53
docs citations

53
times ranked

7895
citing authors

#	ARTICLE	IF	CITATIONS
1	Ubiquitin Ligase Activity and Tyrosine Phosphorylation Underlie Suppression of Growth Factor Signaling by c-Cbl/Sli-1. <i>Molecular Cell</i> , 1999, 4, 1029-1040.	9.7	912
2	Triple negative breast cancer cell lines: One tool in the search for better treatment of triple negative breast cancer. <i>Breast Disease</i> , 2011, 32, 35-48.	0.8	518
3	RINGS of good and evil: RING finger ubiquitin ligases at the crossroads of tumour suppression and oncogenesis. <i>Nature Reviews Cancer</i> , 2011, 11, 629-643.	28.4	347
4	The Death Domain Kinase RIP Is Essential for TRAIL (Apo2L)-Induced Activation of I κ B Kinase and c-Jun N-Terminal Kinase. <i>Molecular and Cellular Biology</i> , 2000, 20, 6638-6645.	2.3	224
5	Safety and Clinical Activity of the Programmed Death-Ligand 1 Inhibitor Durvalumab in Combination With Poly (ADP-Ribose) Polymerase Inhibitor Olaparib or Vascular Endothelial Growth Factor Receptor 1-3 Inhibitor Cediranib in Women's Cancers: A Dose-Escalation, Phase I Study. <i>Journal of Clinical Oncology</i> , 2017, 35, 2193-2202.	1.6	209
6	New insights on PI3K/AKT pathway alterations and clinical outcomes in breast cancer. <i>Cancer Treatment Reviews</i> , 2016, 45, 87-96.	7.7	183
7	Prexasertib, a cell cycle checkpoint kinase 1 and 2 inhibitor, in BRCA wild-type recurrent high-grade serous ovarian cancer: a first-in-class proof-of-concept phase 2 study. <i>Lancet Oncology</i> , The, 2018, 19, 207-215.	10.7	167
8	TRAIL induces apoptosis in triple-negative breast cancer cells with a mesenchymal phenotype. <i>Breast Cancer Research and Treatment</i> , 2009, 113, 217-230.	2.5	157
9	Serine Phosphorylation of Cbl Induced by Phorbol Ester Enhances Its Association with 14-3-3 Proteins in T Cells via a Novel Serine-rich 14-3-3-binding Motif. <i>Journal of Biological Chemistry</i> , 1997, 272, 9979-9985.	3.4	126
10	Combination of PARP Inhibitor Olaparib, and PD-L1 Inhibitor Durvalumab, in Recurrent Ovarian Cancer: a Proof-of-Concept Phase II Study. <i>Clinical Cancer Research</i> , 2020, 26, 4268-4279.	7.0	126
11	Cbl and Human Myeloid Neoplasms: The Cbl Oncogene Comes of Age. <i>Cancer Research</i> , 2010, 70, 4789-4794.	0.9	116
12	Gefitinib response of erlotinib-refractory lung cancer involving meninges—role of EGFR mutation. <i>Nature Clinical Practice Oncology</i> , 2006, 3, 50-57.	4.3	114
13	CIN85 Participates in Cbl-b-mediated Down-regulation of Receptor Tyrosine Kinases. <i>Journal of Biological Chemistry</i> , 2002, 277, 39666-39672.	3.4	108
14	Structural Basis for Ubiquitin-Mediated Dimerization and Activation of the Ubiquitin Protein Ligase Cbl-b. <i>Molecular Cell</i> , 2007, 27, 474-485.	9.7	107
15	CBL Is Frequently Altered in Lung Cancers: Its Relationship to Mutations in MET and EGFR Tyrosine Kinases. <i>PLoS ONE</i> , 2010, 5, e8972.	2.5	98
16	Sequential ubiquitination of NLRP3 by RNF125 and Cbl-b limits inflammasome activation and endotoxemia. <i>Journal of Experimental Medicine</i> , 2020, 217, .	8.5	90
17	Regulating the regulator: negative regulation of Cbl ubiquitin ligases. <i>Trends in Biochemical Sciences</i> , 2006, 31, 79-88.	7.5	88
18	Molecular Pathways: Cbl Proteins in Tumorigenesis and Antitumor Immunity—Opportunities for Cancer Treatment. <i>Clinical Cancer Research</i> , 2015, 21, 1789-1794.	7.0	81

#	ARTICLE	IF	CITATIONS
19	Identification of WEE1 as a potential molecular target in cancer cells by RNAi screening of the human tyrosine kinome. <i>Breast Cancer Research and Treatment</i> , 2010, 122, 347-357.	2.5	77
20	ONC201 kills breast cancer cells <i>in vitro</i> by targeting mitochondria. <i>Oncotarget</i> , 2018, 9, 18454-18479.	1.8	77
21	Tyrosine phosphorylation and complex formation of Cbl-b upon T cell receptor stimulation. <i>Oncogene</i> , 1999, 18, 1147-1156.	5.9	72
22	Chapter 3 The TRAIL to Targeted Therapy of Breast Cancer. <i>Advances in Cancer Research</i> , 2009, 103, 43-73.	5.0	71
23	E3 Ubiquitin Ligase Cbl-b Regulates Pten via Nedd4 in T Cells Independently of Its Ubiquitin Ligase Activity. <i>Cell Reports</i> , 2012, 1, 472-482.	6.4	70
24	E3 Ubiquitin Ligase Cbl-b Suppresses Proallergic T Cell Development and Allergic Airway Inflammation. <i>Cell Reports</i> , 2014, 6, 709-723.	6.4	56
25	cbl-b Inhibits EGF-Receptor-Induced Apoptosis by Enhancing Ubiquitination and Degradation of Activated Receptors. <i>Molecular Cell Biology Research Communications: MCBRC: Part B of Biochemical and Biophysical Research Communications</i> , 1999, 2, 111-118.	1.6	48
26	A Phase II Single Arm Pilot Study of the CHK1 Inhibitor Prexasertib (LY2606368) in <i>BRCA</i> Wild-Type, Advanced Triple-Negative Breast Cancer. <i>Oncologist</i> , 2020, 25, 1013-e1824.	3.7	40
27	Biomarker Assays in Nipple Aspirate Fluid. <i>Breast Journal</i> , 2001, 7, 378-387.	1.0	38
28	Balancing Protein Stability and Activity in Cancer: A New Approach for Identifying Driver Mutations Affecting CBL Ubiquitin Ligase Activation. <i>Cancer Research</i> , 2016, 76, 561-571.	0.9	38
29	The N Terminus of Cbl-c Regulates Ubiquitin Ligase Activity by Modulating Affinity for the Ubiquitin-conjugating Enzyme. <i>Journal of Biological Chemistry</i> , 2010, 285, 23687-23698.	3.4	35
30	TRAIL mediates apoptosis in cancerous but not normal primary cultured cells of the human reproductive tract. <i>Apoptosis: an International Journal on Programmed Cell Death</i> , 2007, 12, 73-85.	4.9	34
31	Phase I/II study of olaparib and carboplatin in women with triple negative breast cancer. <i>Oncotarget</i> , 2017, 8, 79175-79187.	1.8	32
32	WEE1 Inhibition Sensitizes Basal Breast Cancer Cells to TRAIL-Induced Apoptosis. <i>Molecular Cancer Research</i> , 2012, 10, 75-85.	3.4	30
33	2-Methoxyestradiol Mediates Apoptosis Through Caspase-Dependent and Independent Mechanisms in Ovarian Cancer Cells But Not in Normal Counterparts. <i>Reproductive Sciences</i> , 2008, 15, 878-894.	2.5	25
34	Differential expression and signaling of CBL and CBL-B in BCR/ABL transformed cells. <i>Oncogene</i> , 2002, 21, 1423-1433.	5.9	24
35	ONC201: Stressing tumors to death. <i>Science Signaling</i> , 2016, 9, fs1.	3.6	22
36	Temozolomide in secondary prevention of HER2-positive breast cancer brain metastases. <i>Future Oncology</i> , 2020, 16, 899-909.	2.4	22

#	ARTICLE	IF	CITATIONS
37	Enigma Prevents Cbl-c-Mediated Ubiquitination and Degradation of RETMEN2A. PLoS ONE, 2014, 9, e87116.	2.5	21
38	Engineered Multivalency Enhances Affibody-Based HER3 Inhibition and Downregulation in Cancer Cells. Molecular Pharmaceutics, 2017, 14, 1047-1056.	4.6	21
39	ARAP1 association with CIN85 affects epidermal growth factor receptor endocytic trafficking. Biology of the Cell, 2011, 103, 171-184.	2.0	19
40	Mathematical models of breast and ovarian cancers. Wiley Interdisciplinary Reviews: Systems Biology and Medicine, 2016, 8, 337-362.	6.6	19
41	Cbl exposes its RING finger. Nature Structural and Molecular Biology, 2012, 19, 131-133.	8.2	18
42	Cbl-c Ubiquitin Ligase Activity Is Increased via the Interaction of Its RING Finger Domain with a LIM Domain of the Paxillin Homolog, Hic 5. PLoS ONE, 2012, 7, e49428.	2.5	18
43	The TRAIL receptor agonist drozitumab targets basal B triple-negative breast cancer cells that express vimentin and Axl. Breast Cancer Research and Treatment, 2016, 155, 235-251.	2.5	18
44	Analysis of breast cancer in young women in the Department of Defense (DOD) database. Breast Cancer Research and Treatment, 2018, 168, 501-511.	2.5	17
45	Recruitment of Cbl-b to B Cell Antigen Receptor Couples Antigen Recognition to Toll-Like Receptor 9 Activation in Late Endosomes. PLoS ONE, 2014, 9, e89792.	2.5	16
46	Cbl interacts with multiple E2s in vitro and in cells. PLoS ONE, 2019, 14, e0216967.	2.5	15
47	Rare Breast Cancer Subtypes. Current Oncology Reports, 2021, 23, 54.	4.0	15
48	TIC10/ONC201: a bend in the road to clinical development. Oncoscience, 2015, 2, 75-76.	2.2	15
49	Loss of function Cbl-c mutations in solid tumors. PLoS ONE, 2019, 14, e0219143.	2.5	10
50	In Vitro Ubiquitination Platform Identifies Methyl Ellipticiniums as Ubiquitin Ligase Inhibitors. SLAS Discovery, 2021, 26, 870-884.	2.7	5
51	Cbl as a Master Regulator of Receptor Tyrosine Kinase Trafficking. , 2013, , 219-244.		4